Video

Unmet Needs and Clinical Pearls in mCRPC

Author(s):

Neal Shore, MD, FACS

Dr Shore closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing advice for community oncologists.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      Dr Louise Kostos answers a question during a Zoom video interview
      Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
      Dr Louise Kostos answers a question during a Zoom video interview
      An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
      Rana McKay, MD, on the role of radium-223 in the modern era
      Rana McKay, MD, on the role of radium-223 in the modern era
      Dr Louise Kostos answers a question during a Zoom video interview
      Dr Louise Kostos discusses PSA kinetics in mHSPC
      Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
      The importance of PSADT in high-risk, biochemically recurrent prostate cancer
      Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
      Neeraj Agarwal, MD, outlines data on enzalutamide plus talazoparib in mCRPC
      Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
      Expert discusses triplet regimens in metastatic hormone-sensitive prostate cancer
      Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
      Alicia Morgans, MD, MPH, on PSADT awareness and prostate cancer treatment initiation
      Dr Louise Kostos answers a question during a Zoom video interview
      Dr Louise Kostos discusses combination therapies in mHSPC
      Neeraj Agarwal, MD, on the design of the TALAPRO-2 trial
      Neeraj Agarwal, MD, on the design of the TALAPRO-2 trial
      Related Content
      FDA approves expanded label for 177Lu-PSMA-617 in mCRPC
      March 28th 2025

      FDA approves expanded label for 177Lu-PSMA-617 in mCRPC

      Hannah Clarke
      The approval is supported by positive data from the phase 3 PSMAfore trial.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Data reinforce isodose MHFRT as standard of care radiotherapy regimen
      March 22nd 2025

      Data reinforce isodose MHFRT as standard of care radiotherapy regimen

      Hannah Clarke
      “These findings reinforce isodose MHFRT as the standard of care, offering the same cancer control as conventional treatment but with fewer side effects than dose-escalated MHFRT,” says Amar U. Kishan, MD.
      Dr. Schwen on focal therapies for prostate cancer
      January 11th 2024

      Dr. Schwen on focal therapies for prostate cancer

      Cleveland Clinic
      Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
      Trial launches of CBP/p300 inhibitor in mCRPC
      March 20th 2025

      Trial launches of CBP/p300 inhibitor in mCRPC

      Hannah Clarke
      Pocenbrodib is an oral, small molecule designed to inhibit the proteins CREBBP/EP300, which activate genes that promote cancer cell growth and proliferation.
      Exercise may improve erectile function in men with prostate cancer
      March 17th 2025

      Exercise may improve erectile function in men with prostate cancer

      Hannah Clarke
      “The study suggests that exercise would be an effective intervention for men with prostate cancer who express concern about sexual dysfunction, and that exercise medicine should be considered a key part of their treatment,” says Daniel Galvão, PhD.
      © 2025 MJH Life Sciences

      All rights reserved.